|
Canada-0-HOSPITALS कंपनी निर्देशिकाएँ
|
कंपनी समाचार :
- Theravance Biopharma, Inc. (TBPH) Stock Price, News, Quote History . . .
Find the latest Theravance Biopharma, Inc (TBPH) stock quote, history, news and other vital information to help you with your stock trading and investing
- Theravance Biopharma, Inc. (TBPH) - Yahoo Finance
TBPH to Sell Remaining Trelegy Royalty Interest to GSK, Stock Rises Theravance to sell its remaining Trelegy royalty interest to GSK for $225M, with shares jumping 22% on the deal's announcement
- Theravance Biopharma, Inc. (TBPH) Interactive Stock Chart - Yahoo Finance
TBPH to Sell Remaining Trelegy Royalty Interest to GSK, Stock Rises Zacks • 17 days ago Theravance Biopharma, Inc Sells Remaining Royalty Interest in Trelegy Ellipta to GSK for $225 Million
- Theravance Biopharma, Inc. (TBPH) Stock Historical Prices Data . . .
Discover historical prices for TBPH stock on Yahoo Finance View daily, weekly or monthly format back to when Theravance Biopharma, Inc stock was issued
- TBPH Interactive Stock Chart - Yahoo Finance
At Yahoo Finance, you get free stock quotes, up-to-date news, portfolio management resources, international market data, social interaction and mortgage rates that help you manage your financial life
- TBPH to Sell Remaining Trelegy Royalty Interest to GSK, Stock Rises
The stock has rallied 18 5% so far this year against the industry’s decline of 1 9% Zacks Investment Research TBPH Focus on Yupelri Commercialization Other Pipeline Update
- Theravance Biopharma, Inc. (TBPH) Analyst Ratings, Estimates . . .
See Theravance Biopharma, Inc (TBPH) stock analyst estimates, including earnings and revenue, EPS, upgrades and downgrades
- Theravance Biopharma (TBPH) Reports Q1 Loss, Misses Revenue Estimates
Theravance Bio (TBPH) delivered earnings and revenue surprises of -54 55% and 4 20%, respectively, for the quarter ended March 2025 Do the numbers hold clues to what lies ahead for the stock?
- Theravance Biopharma, Inc. (TBPH) - Yahoo Finance
See the company profile for Theravance Biopharma, Inc (TBPH) including business summary, industry sector information, number of employees, business summary, corporate governance, key executives
- Heres Why You May Invest in Theravance (TBPH) Stock Now
TBPH plans to submit regulatory filings for ampreloxetine if data from the CYPRESS study is found to be positive Shares of Theravance have declined 25 3% year to date compared with the industry
|
|